867065-85-8

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL TETRAHYDROPYRIMIDINE-1(2H)-CARBOXYLATE is used as a key intermediate in the synthesis of HAT inhibitors for the development of potential therapeutic agents. These inhibitors target histone acetyltransferases (HATs), enzymes that play a crucial role in the regulation of gene expression and are implicated in various diseases, including cancer and neurodegenerative disorders.
Used in Agrochemical Industry:
TERT-BUTYL TETRAHYDROPYRIMIDINE-1(2H)-CARBOXYLATE is also utilized as a precursor in the production of agrochemicals, specifically in the development of novel pesticides and herbicides. Its unique chemical properties allow for the creation of compounds with improved efficacy and selectivity, contributing to more sustainable agricultural practices.

Upstream product

• 867065-84-7 tert-butyl 5,6-dihydropyrimidine-1(4H)-carboxylate 
• 505-21-5 hexahydropyrimidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

Amidines analogs thereof to catalyze the nitrogen mixed fat surrounds uncle-butoxy carbonyl list protection method (by machine translation)

The present invention is a method under the catalysis of the analogs of the amidines, to two nitrogen heterolipid animal fat link Boc protection of single green synthesis method. It is characterized in that the various two nitrogen heterolipid animal fat link compound water and alcohol as the solvent, in the presence of a certain amount of acid, joins the trunk and its analogs catalyst, di-T-butyl ester for (Boc anhydride) as Boc protecting reagent, the temperature of the reaction is carried out, the final by reduced pressure distillation to obtain the target product is separated from the single N - Boc - two nitrogen heterolipid [...] compound. The invention innovative use of the amidines its analogues as single Boc protecting catalyst, more traditional synthetic method more green environmental protection, safety, and cost saving. (by machine translation)

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

Inhibitors of histone deacetylase

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.